This past year, ABC2 called upon the FDA, Genentech and the NCI’s Radiation Therapy Oncology Group, to harmonize the data generated in the various Avastin trials.
Coordination between the groups would provide better data for the FDA as it considers final approval for the use of Avastin in treating GBM. It would also provide better information for patients and physicians regarding the risks and benefits of using Avastin to treat GBM.
This topic continues to draw a lot of attention in the field.
Click HERE to read a recent article from Medscape discussing an article released in the February 20 issue of the New England Journal of Medicine on this topic. ABC2’s petitioning of the FDA is noted.